Oruka Therapeutics, Inc.
ORKA
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.96B
Close$
$0.99
99.1% downside
Current Fair Value
99.1% downsideOvervalued by 99.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.96 Billion |
|---|---|
| Enterprise Value | $5.91 Billion |
| Dividend Yield | $19.36 (-) |
| Earnings per Share | $-2.31 |
| Beta | -0.39 |
| Outstanding Shares | 55,172,410 |
Return
| Return on Equity | -23.89% |
|---|---|
| Return on Assets | -23.04% |
| Return on Invested Capital | -27.35% |
Valuation & Multiples
| P/E Ratio | -41.35 |
|---|---|
| PEG | -80.24 |
| Price to Sales | - |
| Price to Book Ratio | 13.43 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -44.31 |
| Enterprise Value to Net Income | -51 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 17, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0000▼ 112.87% |
|---|---|
| Total Calls | 800▼ 98.02% |
| Total Puts | 800▼ 99.07% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.14%▼ 70.14% |
|---|---|
| Total Invested | $1.27B▼ 50.30% |
| Investors Holding | 88▼ 99.00% |
ESG Score
No data
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.